XML 50 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Note 4 - Business Combination (Details Textual)
$ / shares in Units, $ in Thousands, € in Millions
 1 Months Ended 12 Months Ended
Oct. 02, 2026
USD ($)
Oct. 02, 2025
USD ($)
Oct. 02, 2024
USD ($)
$ / shares
shares
Apr. 05, 2022
Sep. 30, 2024
USD ($)
$ / shares
shares
Oct. 02, 2026
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
shares
Oct. 02, 2024
EUR (€)
shares
Payments to Acquire Intangible Assets             $ 9,988 $ 775 $ 2,750  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares             359,116      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares             $ 5.46      
Payments to Acquire Businesses, Gross             $ 30,000 $ (0) $ (0)  
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]     Secured Overnight Financing Rate (SOFR) [Member]              
Common Stock Warrants [Member]                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares         289,736       632,231  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares         $ 5.32          
The Amended Agreement [Member] | SWK Holdings Corporation [Member]                    
Line Of Credit Facility, Additional Borrowing Capacity     $ 25,700   $ 25,700          
Line of Credit Facility, Maximum Borrowing Capacity     $ 30,000   $ 30,000          
Debt Instrument, Term (Year)     3 years   3 years          
Debt Instrument, Basis Spread on Variable Rate     6.75% 8.00% 6.75%   8.26%      
Ipsen Biopharmaceuticals, Inc [Member]                    
Payments to Acquire Intangible Assets     $ 22,500              
Payments to Acquire Inventory     7,500              
Business Combination, Contingent Consideration, Liability     2,500              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | €                   € 15
Business Combination, Consideration Transferred, Liabilities Incurred [1]     4,276              
Payments to Acquire Businesses, Gross     30,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory [2]     13,010              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 21,250              
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)     10 years              
Goodwill, Acquired During Period     $ 16              
Business Combination, Acquisition Related Costs             $ 415      
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual             $ 166      
Ipsen Biopharmaceuticals, Inc [Member] | Forecast [Member]                    
Payments to Acquire Businesses, Gross $ 2,500 $ 2,500                
Accretion Expense           $ 724        
Ipsen Biopharmaceuticals, Inc [Member] | Fair Value Adjustments [Member]                    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory     5,510              
Ipsen Biopharmaceuticals, Inc [Member] | As Recorded by Acquiree [Member]                    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory     7,500              
Ipsen Biopharmaceuticals, Inc [Member] | Reported Value Measurement [Member]                    
Business Combination, Consideration Transferred, Liabilities Incurred     $ 5,000              
Ipsen Biopharmaceuticals, Inc [Member] | Common Stock Warrants [Member]                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     289,736             289,736
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares     $ 5.32              
[1] Deferred payments represent the acquisition date fair value of the $5,000 in deferred consideration to be paid to Ipsen. The Company will make payments of $2,500 on each of the first and second anniversaries of closing, which the closing date of the acquisition was December 19, 2024. The Company will accrete the $724, which represents the difference between the total deferred payments amount due of $5,000 and the acquisition date fair value of $4,276, to interest expense in its Statements of Operations over the course of the two-year period using the effective interest rate methodology.
[2] Inventory consists of raw materials, semi-finished goods and finished goods. Finished goods, semi-finished goods and raw materials inventory were valued on the acquisition date at fair value and resulted in a $5,510 step-up in inventory value compared to a $7,500 carrying value. Determining the fair value of inventory included making estimates of costs to complete and to sell semi-finished and finished goods inventory.